Author's details
- Owoseni Opeyemi
- MBBS, FMCP
- FMC Abeokuta, Ogun State Nigeria.
Reviewer's details
- Dr Olasoji Ibidapo
- Consultant physician/endocrinologist
- Ekiti state University Teaching Hospital.
- Date Uploaded: 2026-11-20
- Date Updated: 2026-11-20
Hepatitis B
Key Messages
- Hepatitis B remains a major global and Nigerian public-health problem, causing substantial illness and death from cirrhosis and hepatocellular carcinoma.
- HBV is transmitted through infected blood and body fluids, especially during childbirth, early-childhood exposure, sexual contact, unsafe injections and contact with contaminated sharp instruments.
- Most acute and chronic infections are asymptomatic; the risk of chronic infection is highest when HBV is acquired at birth or in early childhood.
- Diagnosis and assessment require HBV serology, HBV DNA testing, liver-function evaluation and assessment for fibrosis, cirrhosis and hepatocellular carcinoma.
- Vaccination—particularly a timely birth dose—is the most effective preventive measure, while eligible patients with chronic hepatitis B benefit from antiviral treatment and regular monitoring.
Hepatitis is inflammation of the liver. It may be caused by viruses, alcohol use, toxins and medications. Common viral causes –the Hepatitides i.e. Hepatitis A, B and C and less commonly Hepatitis D and E. Other less common causes of viral hepatitis are adenovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV) and, rarely, herpes simplex virus (HSV).
Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus in the family Hepadnaviridae. Its incubation period is approximately 1–4 months. According to WHO estimates for 2024, about 240 million people were living with chronic hepatitis B, approximately 0.9 million new infections occurred, and about 1.1 million people died, mainly from cirrhosis and hepatocellular carcinoma. The greatest burden remains in the WHO Western Pacific and African regions.
Nigeria remains a high-burden country. A national survey published in 2016 reported an HBsAg prevalence of 12.2%, while a 2021 systematic review and meta-analysis estimated a pooled prevalence of 9.5%. The review by Olakunde et al. reported general-population prevalence estimates ranging from 5.4% to 13.6%, with the most recent national estimate of 5.4% in 2022, corresponding to approximately 14.4 million people living with HBV. Prevalence varies by population, sex, age, residence and geographical region; genotype E predominates.
Modes of transmission
HBV is transmitted through exposure to infected blood and body fluids. Important routes include:
- Mother-to-child transmission during childbirth, particularly in highly endemic settings.
- Horizontal transmission during early childhood through contact with infected blood or open sores.
- Sexual contact with an infected person.
- Unsafe injections, transfusion of unscreened blood, needle-stick injuries and sharing contaminated needles or syringes.
- Sharing contaminated sharp personal items, including razors, clippers and manicure or pedicure instruments.
- Tattooing, piercing or other procedures performed with inadequately sterilised equipment.
HBV is not spread by casual contact such as hugging, coughing, sneezing, or sharing food and eating utensils.
Hepatitis B virus belongs to the family of Hepadnaviruses, which include duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. The complete virion or Dane particle is 42 nm in diameter. It consists of:
- An envelope - made up of viral-encoded proteins and host-derived lipid components.
- A core particle -made up of the nucleocapsid protein, the viral genome, and the polymerase protein.
Symptoms
This usually depends on whether its acute (lasting < 6 months) or chronic (lasting ≥ 6 months).
Acute Hepatitis
Asymptomatic in 70%. Symptoms may include malaise, arthralgia, +/- jaundice. Usually self-limiting in adults. Post-exposure to symptoms ≈ 60 -90 days. Progression to CHBV depends on age at acquisition. 90% for a perinatally acquired. 20 – 50% are acquired at 1-5years. <5 % for adult-acquired infection. Liver failure in <1%.
Chronic- Hepatitis
Usually asymptomatic- 70-80%. Arthralgia, frequent feverish feelings. May transition through the defined clinical phases. 20-25% may develop complications with features such as jaundice, ascites, coagulopathy, abdominal pain, GI bleeding and hepatic encephalopathy.
Clinical findings
Usually asymptomatic, but in the acute phase there may be jaundice. In the chronic phase there may be no abnormalities in most patients, or there may be features of liver cirrhosis or longstanding liver disease such as gynaecomastia in men, parotid fullness, fluffy hair, leukonychia, wasting of the thenar and hypothenar eminences on the palms, finger clubbing, palmar erythema, spider naevi and testicular atrophy. There may also be features of hepatic decompensation such as jaundice, ascites, hepatic encephalopathy and caput medusae.
Differential diagnoses
Differential diagnoses depend on whether the presentation is acute or chronic.
Acute Hepatitis
- Other acute viral hepatitis, including hepatitis A, C and E.
- Acute cholecystitis.
- Acute cholangitis or other causes of biliary obstruction.
- Drug- or toxin-induced liver injury.
- Ischaemic hepatitis.
- Acute autoimmune hepatitis.
- Febrile illnesses such as malaria and systemic viral or bacterial infection.
Chronic Hepatitis
- Chronic hepatitis C or hepatitis D infection.
- Alcohol-associated liver disease.
- Drug- or toxin-induced chronic hepatitis.
- Autoimmune hepatitis.
- Metabolic dysfunction-associated steatotic liver disease.
- Hereditary and metabolic liver diseases, including Wilson disease, haemochromatosis and alpha-1 antitrypsin deficiency.
- Other causes of cirrhosis and portal hypertension.
Yellow discoloration of the sclera (jaundice): - yellow fever, decompensated liver cirrhosis from any other cause, cholestatic liver disease,
Abdominal distension (ascites or liver mass): -ascites from other causes like Nephrotic syndrome, TB peritonitis, peritoneal carcinomatosis, right ventricular failure
Sleep disorders or irrational behaviour: - dementia, insomnia, psychiatric disorders
Bleeding diathesis: - Viral haemorrhagic fevers (Lassa, Ebola, Dengue fevers etc) coagulopathies from leukaemia, auto-immune disease, Disseminated Intravascular Coagulopathy (DIC).
Upper Gastrointestinal bleeding: - bleeding upper gastrointestinal ulcers, bleeding diathesis, bleeding upper gastrointestinal cancers
Investigations
Full blood count- anaemia, low platelets, raised white cell count (with sepsis)
Liver enzymes- elevated ALT with degree of liver parenchymal damage, elevated AST with alcoholic involvement or fibrosis, elevated bilirubin levels with deteriorating liver functions
Hepatitis B profile- helps confirm the infection and occasionally the infectivity of the patient
Other possible co-infections like Hepatitis C and HIV- this helps decide on the treatment protocol.
Hepatitis B Viral DNA quantification
Abdominal Ultrasound scan- Looks at the size, echogenicity of the liver and presence of a liver mass (suggestive of a tumour). It also looks for ascites and splenic enlargement.
Alpha-fetoprotein- serves as a tumour marker for Hepatocellular Carcinoma in some patients.
Treatment
At the core of therapy is counselling. The individual must understand the nature of the disorder and transmission routes, in order to understand how he got infected and how to reduce spread. In addition, lifestyle changes to reduce the risk of on-going liver damage and progression.
Treatment depends on the prevailing guidelines and the condition of the patient. In our practice, we use the WHO guidelines because it is designed for low-income countries like ours. Once there are no complications, no evidence of inflammation, no family history of liver disease, no co-morbidities or co-infections and no fibrosis/cirrhosis, most guidelines will defer treatment. Treatment usually involves using a Nucleoside/nucleotide analogue such as Tenofovir or Entecavir and in occasional cases, Pegylated Interferon alpha injections in select cases.
Follow up.
For Acute Hepatitis, management is largely conservative or supportive, i.e., rehydrate if dehydrated, bed rest, balanced diet for feeding, analgesics for body aches and anti-pyretic for fever.
In the event of rare cases of acute liver failure, the patient may require ICU admission and management.
For Chronic, asymptomatic patients- Regular 3-monthly or 6-monthly follow-ups for surveillance is important. Liver enzymes, alpha-fetoproteins, liver scans and the HBV viral load are checked from time to time.
Prevention and control
Prevention includes getting the very effective Hepatitis B vaccine, especially at birth. The unvaccinated adult needs to first confirm his status by carrying out a screening test and then get vaccinated if negative. Other preventive measures include avoidance of sharing sharps/sharp objects (blades, barbing clippers, manicure/pedicure sets etc), unsafe injection practices and unhealthy sexual practices.
Conclusion
Hepatitis B is a disease of global concern with high mortality and mortality. It is largely asymptomatic and discovered only when tested for it or when there are complications. Vaccination is highly effective and has helped lower the prevalence and incidence over the last 20 years.
A 34-year-old man was found to be HBsAg-positive during a routine pre-employment screening. He had no symptoms, no jaundice, no alcohol use and no family history of liver disease. His mother was known to be a carrier, and he had not been vaccinated at birth. Examination showed no stigmata of chronic liver disease, ascites or hepatomegaly.
Investigations showed normal liver enzymes and a normal full blood count. The Hepatitis B profile confirmed HBsAg positivity with negative HBeAg, HIV and Hepatitis C screening were negative, and HBV DNA was low. Abdominal ultrasound and alpha-fetoprotein were normal.
He was counselled on transmission and lifestyle measures, and his household contacts were screened and vaccinated where non-immune. As he had no evidence of inflammation, fibrosis or cirrhosis, antiviral treatment was deferred in line with prevailing guidelines. He was placed on 6-monthly follow-up with liver enzymes, HBV DNA, alpha-fetoprotein and ultrasound surveillance.
Chart
Related Topics
- World Health Organization. Hepatitis B [Internet]. Geneva: World Health Organization; 2026 [cited 2026 Oct 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- World Health Organization. Global hepatitis report 2026. Geneva: World Health Organization; 2026.
- World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.
- World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
- Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, et al. Seroprevalence of hepatitis B infection in Nigeria: a national survey. Am J Trop Med Hyg. 2016;95(4):902-7. doi:10.4269/ajtmh.15-0874.
- Ajuwon BI, Yujuico I, Roper K, Richardson A, Sheel M, Lidbury BA. Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019. BMC Infect Dis. 2021;21:1120. doi:10.1186/s12879-021-06800-6.
- Olakunde BO, Adeyinka DA, Olakunde OA, Eneh SC, Ogundipe T. Epidemiology of hepatitis B virus infection in Nigeria: a narrative review of prevalence, transmission, genotypes, coinfections, and mortality. J Trop Med. 2025;2025:4939367. doi:10.1155/jotm/4939367.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-83. doi:10.1016/j.jhep.2025.03.018.
- Centers for Disease Control and Prevention. Clinical overview of hepatitis B [Internet]. Atlanta: CDC; 2025 [cited 2026 Oct 24]. Available from: https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html
- Dias JD, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. 2021;13(5):757. doi:10.3390/v13050757.
- Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48-64. doi:10.3748/wjg.v13.i1.48.
Advertise on Medicobridge
More topics to explore
Author's details
Reviewer's details
Hepatitis B
- Background
- Symptoms
- Clinical findings
- Differential diagnosis
- Investigations
- Treatment
- Follow-up
- Prevention and control
- Further readings
Hepatitis is inflammation of the liver. It may be caused by viruses, alcohol use, toxins and medications. Common viral causes –the Hepatitides i.e. Hepatitis A, B and C and less commonly Hepatitis D and E. Other less common causes of viral hepatitis are adenovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV) and, rarely, herpes simplex virus (HSV).
Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus in the family Hepadnaviridae. Its incubation period is approximately 1–4 months. According to WHO estimates for 2024, about 240 million people were living with chronic hepatitis B, approximately 0.9 million new infections occurred, and about 1.1 million people died, mainly from cirrhosis and hepatocellular carcinoma. The greatest burden remains in the WHO Western Pacific and African regions.
Nigeria remains a high-burden country. A national survey published in 2016 reported an HBsAg prevalence of 12.2%, while a 2021 systematic review and meta-analysis estimated a pooled prevalence of 9.5%. The review by Olakunde et al. reported general-population prevalence estimates ranging from 5.4% to 13.6%, with the most recent national estimate of 5.4% in 2022, corresponding to approximately 14.4 million people living with HBV. Prevalence varies by population, sex, age, residence and geographical region; genotype E predominates.
- World Health Organization. Hepatitis B [Internet]. Geneva: World Health Organization; 2026 [cited 2026 Oct 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- World Health Organization. Global hepatitis report 2026. Geneva: World Health Organization; 2026.
- World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.
- World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
- Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, et al. Seroprevalence of hepatitis B infection in Nigeria: a national survey. Am J Trop Med Hyg. 2016;95(4):902-7. doi:10.4269/ajtmh.15-0874.
- Ajuwon BI, Yujuico I, Roper K, Richardson A, Sheel M, Lidbury BA. Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019. BMC Infect Dis. 2021;21:1120. doi:10.1186/s12879-021-06800-6.
- Olakunde BO, Adeyinka DA, Olakunde OA, Eneh SC, Ogundipe T. Epidemiology of hepatitis B virus infection in Nigeria: a narrative review of prevalence, transmission, genotypes, coinfections, and mortality. J Trop Med. 2025;2025:4939367. doi:10.1155/jotm/4939367.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-83. doi:10.1016/j.jhep.2025.03.018.
- Centers for Disease Control and Prevention. Clinical overview of hepatitis B [Internet]. Atlanta: CDC; 2025 [cited 2026 Oct 24]. Available from: https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html
- Dias JD, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. 2021;13(5):757. doi:10.3390/v13050757.
- Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48-64. doi:10.3748/wjg.v13.i1.48.
Content
Author's details
Reviewer's details
Hepatitis B
Background
Hepatitis is inflammation of the liver. It may be caused by viruses, alcohol use, toxins and medications. Common viral causes –the Hepatitides i.e. Hepatitis A, B and C and less commonly Hepatitis D and E. Other less common causes of viral hepatitis are adenovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV) and, rarely, herpes simplex virus (HSV).
Hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus in the family Hepadnaviridae. Its incubation period is approximately 1–4 months. According to WHO estimates for 2024, about 240 million people were living with chronic hepatitis B, approximately 0.9 million new infections occurred, and about 1.1 million people died, mainly from cirrhosis and hepatocellular carcinoma. The greatest burden remains in the WHO Western Pacific and African regions.
Nigeria remains a high-burden country. A national survey published in 2016 reported an HBsAg prevalence of 12.2%, while a 2021 systematic review and meta-analysis estimated a pooled prevalence of 9.5%. The review by Olakunde et al. reported general-population prevalence estimates ranging from 5.4% to 13.6%, with the most recent national estimate of 5.4% in 2022, corresponding to approximately 14.4 million people living with HBV. Prevalence varies by population, sex, age, residence and geographical region; genotype E predominates.
Further readings
- World Health Organization. Hepatitis B [Internet]. Geneva: World Health Organization; 2026 [cited 2026 Oct 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- World Health Organization. Global hepatitis report 2026. Geneva: World Health Organization; 2026.
- World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.
- World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
- Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, et al. Seroprevalence of hepatitis B infection in Nigeria: a national survey. Am J Trop Med Hyg. 2016;95(4):902-7. doi:10.4269/ajtmh.15-0874.
- Ajuwon BI, Yujuico I, Roper K, Richardson A, Sheel M, Lidbury BA. Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019. BMC Infect Dis. 2021;21:1120. doi:10.1186/s12879-021-06800-6.
- Olakunde BO, Adeyinka DA, Olakunde OA, Eneh SC, Ogundipe T. Epidemiology of hepatitis B virus infection in Nigeria: a narrative review of prevalence, transmission, genotypes, coinfections, and mortality. J Trop Med. 2025;2025:4939367. doi:10.1155/jotm/4939367.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-83. doi:10.1016/j.jhep.2025.03.018.
- Centers for Disease Control and Prevention. Clinical overview of hepatitis B [Internet]. Atlanta: CDC; 2025 [cited 2026 Oct 24]. Available from: https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html
- Dias JD, Sarica N, Neuveut C. Early steps of hepatitis B life cycle: from capsid nuclear import to cccDNA formation. Viruses. 2021;13(5):757. doi:10.3390/v13050757.
- Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48-64. doi:10.3748/wjg.v13.i1.48.